New Drug Indications for Pediatric Type 2 Diabetes, Cystic Fibrosis, and Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Liraglutide (Victoza) is now approved for use in children 10 years and older with type 2 diabetes.Tezacaftor–ivacaftor (Symdeko) is now approved for children six years and older with cystic fibrosis and a specific genetic mutation. Previously, the combination drug was approved for children ages 12 and older.The combination antiinfective ceftolozane–tazobactam (Zerbaxa) is now approved to treat hospital-acquired and ventilator-associated bacterial pneumonia in patients 18 years and older. The dose of ceftolozane–tazobactam is higher for this indication than for others.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research